How do Medibank (ASX:MPL) dividends compare to NIB?

How do the dividend yields of these 2 private healthcare insurers stack up for income investors?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

man holding two stacks of coins varying in size representing a comparison of dividend yields between Medibank and NIB

Image source: Getty Images

Key points

  • Medibank Private and NIB are both ASX 200 health insurance heavyweights
  • Both offer robust dividend yields, complete with full franking
  • But which private health insurer comes out on top for income investors?

The Medibank Private Ltd (ASX: MPL) share price is enjoying a pretty positive day on the ASX boards this Friday. At the time of writing, the Medibank share price is up 0.3% at $3.29. That also puts this private health insurer at a robust 11.5% gain for the past 12 months. It also puts its trailing dividend yield at a solid 3.85%.

Given Medibank usually includes full franking credits with its dividends, that means this company is today offering a grossed-up yield of 5.5%. That's objectively not a bad yield from an ASX 200 dividend share. It's more than what Commonwealth Bank of Australia (ASX: CBA) shares are offering right now, for starters.

But how do Medibank dividends compare to those of ASX-listed arch rival NIB Holdings Limited (ASX: NHF)?

Well, let's check out the recent history of the Medibank dividend before we start the comparisons. So that 3.85% trailing yield comes from Medibank's 2 dividend payments doled out in 2021. The first was the interim dividend of 5.8 cents a share that shareholders received last March. The second was the final dividend of 6.9 cents paid in September.

Both payments were fully franked, as flagged earlier. Together, that equates to a total of 12.7 cents per share in dividends for 2021, a hearty increase over the 12 cents per share Medibank dividend paid in 2020. But this is not quite at the high watermark of 15.6 cents per share dividend that Medibank paid in 2019.

So how do those payments compare to that of NIB?

How do Medibank dividends compare to NIB?

Well, to kick things off, NIB shares currently have a trailing yield of 3.64%, based on the current share price of $6.59 that we see today. That grosses-up to 5.2% with full franking credits.

That yield comes from the interim dividend of 10 cents a share that we saw last April. As well as the final dividend of 14 cents per share paid out last October. Both payouts were fully franked. That equates to a 2021 total of 24 cents per share, a record high dividend from NIB.

So it appears that the Medibank dividend is the leader here (if only just) for income investors. We'll have to see if that holds up when both Medibank and NIB's 2022 dividends come through the door.

Medibank share price snapshot

While the Medibank share price is up a healthy 11.5% over the past 12 months, it has weakened in 2022. The share price has fallen by 4% since the year began.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

ASX share investor sitting with a laptop on a desk, pondering something.
Share Fallers

CSL shares crash to a 9-year low. Is it time to sell off my shares?

What's next for the beaten-down ASX biotech stock?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

This ASX biotech hit a 90% success rate. Can it unlock commercial growth?

Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

This ASX biotech is pushing for a Nasdaq listing. Could it reignite investor interest?

The NASDAQ has a reputation for providing a platform for some of the world's most innovative companies.

Read more »

Smiling health care workers in a medical setting.
Healthcare Shares

3 ASX healthcare shares to buy amid sector rout: experts

Healthcare shares have tumbled 36% over the past year amid multiple headwinds for the sector.

Read more »

Person pressing the buy button on a smartphone.
Broker Notes

3 reasons to buy Pro Medicus shares today

A leading analyst believes Pro Medicus shares are now trading at a significant discount.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX biotech has just announced a major US deal

This company's heart disease technology is gaining traction.

Read more »

Devastated woman sits near smartphone on home kitchen floor troubled with loneliness.
Healthcare Shares

Which beaten down ASX healthcare stock is a better buy right now: Pro Medicus vs Cochlear shares

Which do experts prefer?

Read more »

Health professional working on his laptop.
Healthcare Shares

Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket

This broker sees big upside for this healthcare stock.

Read more »